In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Coherus Biosciences (NASDAQ: CHRS), with a price target of $45. The company’s shares closed yesterday at $12.30.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 2.3% and a 44.3% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Adamas Pharmaceuticals, and Amag Pharmaceuticals.
Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $32.67, a 165.6% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
Based on Coherus Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $43.64 million. In comparison, last year the company had a GAAP net loss of $58.99 million.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CHRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar.